This law promised medical hope for dying patients. Was it a cruel deception? bridgemi.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bridgemi.com Daily Mail and Mail on Sunday newspapers.
FPI-2265 showed promising activity in patients with metastatic castration-resistant prostate cancer which was similar to prior safety and efficacy data reported.
Trial's Objective Response Rate Endpoint Already Achieved RadioMedix and Orano Med, two clinical stage radiopharmaceutical companies, today announced that the last patient has been dosed in the Phase
/PRNewswire/ Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) ("Fusion"), a clinical-stage oncology company focused on developing next-generation targeted alpha.
Fusion Pharmaceuticals (FUSN) Announces 17.6M Share Offering at $3.40/sh, Acquires Phase 2 Program for 225Ac-PSMA I&T streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.